Ainos, Inc. (AIMD)
NASDAQ: AIMD · Real-Time Price · USD
0.455
+0.001 (0.13%)
Dec 30, 2024, 4:00 PM EST - Market closed
Ainos Revenue
Ainos had revenue of $40.63K in the twelve months ending September 30, 2024, down -96.44% year-over-year. In the year 2023, Ainos had annual revenue of $122.11K, down -96.53%.
Revenue (ttm)
$40.63K
Revenue Growth
-96.44%
P/S Ratio
78.10
Revenue / Employee
$883
Employees
46
Market Cap
6.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 122.11K | -3.40M | -96.53% |
| Dec 31, 2022 | 3.52M | 2.93M | 491.97% |
| Dec 31, 2021 | 594.56K | 578.00K | 3,489.71% |
| Dec 31, 2020 | 16.56K | 4.83K | 41.19% |
| Dec 31, 2019 | 11.73K | -65.99K | -84.91% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
AIMD News
- 12 days ago - CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - Accesswire
- 12 days ago - Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA - Accesswire
- 17 days ago - Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement - Accesswire
- 26 days ago - Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing - Accesswire
- 4 weeks ago - Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug - Newsfile Corp
- 6 weeks ago - Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments - Accesswire
- 7 weeks ago - Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025 - Accesswire
- 7 weeks ago - Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities - Accesswire